select a format

Single User License
USD 2000 INR 128820
Site License
USD 4000 INR 257640
Corporate User License
USD 6000 INR 386460

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Review, H2 2015

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Review, H2 2015


  • Products Id :- GMDHC6875IDB
  • |
  • Pages: 98
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Review, H2 2015', provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Secondary Progressive Multiple Sclerosis (SPMS)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Secondary Progressive Multiple Sclerosis (SPMS) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Secondary Progressive Multiple Sclerosis (SPMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Secondary Progressive Multiple Sclerosis (SPMS) Overview 7

Therapeutics Development 8

Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS)-Overview 8

Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS)-Comparative Analysis 9

Secondary Progressive Multiple Sclerosis (SPMS)-Therapeutics under Development by Companies 10

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Secondary Progressive Multiple Sclerosis (SPMS)-Products under Development by Companies 15

Secondary Progressive Multiple Sclerosis (SPMS)-Companies Involved in Therapeutics Development 16

AB Science SA 16

Biogen, Inc. 17

Daval International Limited 18

Genzyme Corporation 19

Glialogix, Inc. 20

Immune Response BioPharma, Inc. 21

Innate Immunotherapeutics Limited 22

Kyorin Pharmaceutical Co., Ltd. 23

MedDay 24

Merck KGaA 25

Novartis AG 26

Opexa Therapeutics, Inc. 27

Secondary Progressive Multiple Sclerosis (SPMS)-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

Aimspro-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ApE-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

ATXMS-1467-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

biotin-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

DC-TAB-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

GLX-1112-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

GZ-402668-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

ibudilast-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

imilecleucel-t-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

interferon beta-1b-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

IR-902-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

masitinib-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

MIS-416-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

natalizumab-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

opicinumab-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

OSX-110-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

siponimod-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Secondary Progressive Multiple Sclerosis (SPMS)-Recent Pipeline Updates 65

Secondary Progressive Multiple Sclerosis (SPMS)-Discontinued Products 89

Secondary Progressive Multiple Sclerosis (SPMS)-Product Development Milestones 90

Featured News & Press Releases 90

Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 90

Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 90

Oct 07, 2014: Update on Innate's Phase 2B trial and other recent activities 91

Aug 19, 2014: Innate's Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval 91

Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis 92

Jun 18, 2014: Compassionate Use Programme Update 93

May 13, 2014: Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis 94

Apr 15, 2014: Innate Immunotherapeutics confirms Phase 2B trial on track and on budget 94

Mar 11, 2014: Innate Immunotherapeutics receives EU patent protection for use of MIS416 to treat or prevent radiation injury 95

Feb 03, 2014: Dr Larry Steinman, renowned multiple sclerosis specialist at Stanford University, endorses newly published MIS416 therapy validation in animal studies 95

Appendix 97

Methodology 97

Coverage 97

Secondary Research 97

Primary Research 97

Expert Panel Validation 97

Contact Us 97

Disclaimer 98

List of Tables

Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2015 8

Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS)-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 11

Comparative Analysis by Late Stage Development, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 13

Comparative Analysis by Early Stage Development, H2 2015 14

Products under Development by Companies, H2 2015 15

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by AB Science SA, H2 2015 16

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Biogen, Inc., H2 2015 17

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Daval International Limited, H2 2015 18

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Genzyme Corporation, H2 2015 19

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Glialogix, Inc., H2 2015 20

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Immune Response BioPharma, Inc., H2 2015 21

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Innate Immunotherapeutics Limited, H2 2015 22

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015 23

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by MedDay, H2 2015 24

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Merck KGaA, H2 2015 25

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Novartis AG, H2 2015 26

Secondary Progressive Multiple Sclerosis (SPMS)-Pipeline by Opexa Therapeutics, Inc., H2 2015 27

Assessment by Monotherapy Products, H2 2015 28

Number of Products by Stage and Target, H2 2015 30

Number of Products by Stage and Mechanism of Action, H2 2015 32

Number of Products by Stage and Route of Administration, H2 2015 34

Number of Products by Stage and Molecule Type, H2 2015 36

Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics-Recent Pipeline Updates, H2 2015 65

Secondary Progressive Multiple Sclerosis (SPMS)-Discontinued Products, H2 2015 89

List of Figures

Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS), H2 2015 8

Number of Products under Development for Secondary Progressive Multiple Sclerosis (SPMS)-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 13

Assessment by Monotherapy Products, H2 2015 28

Number of Products by Top 10 Targets, H2 2015 29

Number of Products by Stage and Top 10 Targets, H2 2015 29

Number of Products by Top 10 Mechanism of Actions, H2 2015 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 31

Number of Products by Top 10 Routes of Administration, H2 2015 33

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 33

Number of Products by Top 10 Molecule Types, H2 2015 35

Number of Products by Stage and Top 10 Molecule Types, H2 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science SA

Biogen, Inc.

Daval International Limited

Genzyme Corporation

Glialogix, Inc.

Immune Response BioPharma, Inc.

Innate Immunotherapeutics Limited

Kyorin Pharmaceutical Co., Ltd.

MedDay

Merck KGaA

Novartis AG

Opexa Therapeutics, Inc.

Secondary Progressive Multiple Sclerosis (SPMS) Therapeutic Products under Development, Key Players in Secondary Progressive Multiple Sclerosis (SPMS) Therapeutics, Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Overview, Secondary Progressive Multiple Sclerosis (SPMS) Pipeline, Secondary Progressive Multiple Sclerosis (SPMS) Pipeline Assessment


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com